Title:Verification between Original and Biosimilar Therapeutic Antibody Infliximab Using nSMOL Coupled LC-MS Bioanalysis in Human Serum
VOLUME: 19 ISSUE: 6
Author(s):Noriko Iwamoto, Kotoko Yokoyama, Megumi Takanashi, Atsushi Yonezawa, Kazuo Matsubara and Takashi Shimada*
Affiliation:Leading Technology of Bioanalysis and Protein Chemistry, Shimadzu Corporation, Kyoto, Leading Technology of Bioanalysis and Protein Chemistry, Shimadzu Corporation, Kyoto, Leading Technology of Bioanalysis and Protein Chemistry, Shimadzu Corporation, Kyoto, Department of Clinical Pharmacology and Therapeutics, Kyoto University Hospital, Kyoto, Department of Clinical Pharmacology and Therapeutics, Kyoto University Hospital, Kyoto, Leading Technology of Bioanalysis and Protein Chemistry, Shimadzu Corporation, Kyoto
Keywords:Infliximab, biosimilar, nSMOL, LC-MS, bioanalysis, clinical pharmacokinetics, therapeutic drug monitoring.
Abstract:Background: Infliximab (IFX) is a chimeric therapeutic monoclonal antibody targeting tumor
necrosis factor alpha (TNFα)-mediated inflammatory immune diseases. However, despite of an
initial good clinical response, decrease in response to long-term treatment is a common observation.
Objective: Recent studies suggest that IFX level in circulation has a correlation with clinical bioavailability.
Therefore, the management of IFX dosage for individual manifestation by IFX monitoring may
be valuable for the improvement of therapeutic response and outcomes.
Method: In order to develop a broad IFX therapeutic monitoring in human serum, we have developed
the validated IFX bioanalysis for RemicadeTM and its biosimilar product using our nano-surface and
molecular-orientation limited proteolysis (nSMOL) technology coupled with liquid chromatographytandem
mass spectrometry (LC-MS/MS). The nSMOL chemistry has a unique property of Fabselective
proteolysis, and makes it possible a global bioanalysis for many monoclonal antibodies.
Results: The quantitation range of IFX in serum was from 0.293 to 300 μg/ml with good linearity.
Quantitation verification at the concentrations of 0.293, 0.879, 14.1 and 240 µg/ml was within 1.56-
7.53% of precision and 98.9-111% of accuracy using H-chain signature peptide SINSATHYAESVK.
Moreover, cross-verified bioanalysis of Remicade quantitation using biosimilar standard, and its opposite
combination, obtained an identical and inter-comparative results.
Conclusion: The nSMOL strategy has the potential as a practical therapeutic monitoring technology in
IFX therapeutic applications.
